The Journal of Computational Biophysics and Chemistry, published by World Scientific Publishing Co. Pte Ltd, is a distinguished platform dedicated to advancing the fields of biophysics and computational chemistry. With an ISSN of 2737-4165 and an E-ISSN of 2737-4173, this journal has garnered attention since its inception, earning a Q3 ranking in Computational Theory and Mathematics and Q4 rankings in both Computer Science Applications and Physical and Theoretical Chemistry as of 2023. The scope of the journal encompasses innovative research that integrates computational techniques with biochemical applications, making it essential reading for researchers, professionals, and students alike. With open access options available, the journal ensures that cutting-edge findings are easily accessible to a global audience, thereby fostering collaboration and innovation in the scientific community. Based in Singapore, the journal aims to converge ideas and methodologies from 2021 to 2024, paving the way for transformative insights in computational methods. Join a community at the forefront of research and applications that bridge disciplines through rigorous scholarship and pioneering discoveries.

Letters in Drug Design & Discovery is an esteemed journal dedicated to advancing the fields of Drug Discovery and Molecular Medicine. Published by Bentham Science Publishers, this journal offers a platform for the dissemination of innovative research and advanced methodologies, enhancing collaboration among researchers and professionals in pharmaceutical sciences. Despite its current Q4 ranking in Drug Discovery and Molecular Medicine and Q3 in Pharmaceutical Science for 2023, the journal is committed to improving its presence in the academic community by providing quality, peer-reviewed publications that cover various aspects of drug design and discovery, including novel therapeutic approaches and methodologies. With a focus on both foundational and cutting-edge research from around the globe, Letters in Drug Design & Discovery is pivotal for those seeking to stay abreast of developments in drug development and molecular research. Researchers are encouraged to submit their work, engage with the burgeoning field, and contribute to the ongoing dialogue driven by this journal, which spans the years from 2005 to 2024. While the journal does not currently offer open access, its contributions remain accessible to a wide range of academic and professional audiences.

CURRENT PHARMACEUTICAL DESIGN is a leading journal in the fields of Drug Discovery and Pharmacology, published by Bentham Science Publishers Ltd in the dynamic United Arab Emirates. With an impressive historical span from 1995 to 2024, this journal serves as a vital platform for disseminating innovative research findings, breakthrough methodologies, and critical reviews that shape the future of pharmaceutical sciences. Ranked Q2 in both Drug Discovery and Pharmacology categories according to the 2023 metrics, it places itself within the top-tier percentile, catering to a diverse audience of researchers, industry professionals, and students. The journal’s commitment to high-quality research exploration is evidenced by its Scopus ranking, where it is positioned favorably within its category ranks. Although currently not Open Access, CURRENT PHARMACEUTICAL DESIGN remains an essential resource for those looking to stay at the forefront of pharmacological advancements and drug development strategies.

JOURNAL OF ENZYME INHIBITION AND MEDICINAL CHEMISTRY, published by Taylor & Francis Ltd, is a premier open-access journal that has been at the forefront of research in the field of medicinal chemistry since its inception in 1985. With an ISSN of 1475-6366 and an E-ISSN of 1475-6374, this journal boasts a prestigious reputation reflected in its impressive Q1 rankings across critical categories such as Drug Discovery and Pharmacology as of 2023. Situated in the United Kingdom, it plays a vital role in disseminating high-quality research that addresses the burgeoning needs of drug discovery and enzyme inhibition methodologies. The journal supports full open access, providing a platform for researchers, professionals, and students to share significant findings and innovations widely. With a robust impact factor, the JOURNAL OF ENZYME INHIBITION AND MEDICINAL CHEMISTRY is indispensable for any academic or professional involved in the pharmacological sciences, offering an unparalleled insight into the latest advancements in therapeutic strategies and drug development.

JOURNAL OF ASIAN NATURAL PRODUCTS RESEARCH is a prestigious publication in the field of natural products, focusing on valuable research spanning analytical chemistry, pharmacology, and complementary medicine. Published by Taylor & Francis Ltd in the United Kingdom, this journal has established itself as a key resource for academics and professionals seeking to explore advancements in drug discovery and organic chemistry. With a converged publication timeline from 1998 to 2024, the journal boasts several commendable category quartiles as of 2023, reflecting its robust standing in the research community: Q2 in Complementary and Alternative Medicine, Q3 in multiple domains including Analytical Chemistry and Organic Chemistry, and Q4 in Molecular Medicine. Although it currently does not offer open access, the journal remains a valuable compendium for empirical research and innovative studies in areas such as pharmacology and medicinal chemistry. Researchers, professionals, and students alike will find the JOURNAL OF ASIAN NATURAL PRODUCTS RESEARCH to be an essential platform for sharing groundbreaking findings and fostering collaborations that lead to significant advancements in science and health.

NATURAL PRODUCT RESEARCH is a distinguished journal published by Taylor & Francis Ltd, dedicated to advancing the field of natural product science through the dissemination of high-quality research. Established in 2003, this journal serves as a pivotal platform for scholars in Analytical Chemistry, Biochemistry, Organic Chemistry, and Plant Science, boasting an impressive categorization including Q2 in Plant Science and Q3 in the other disciplines for 2023. With a current Scopus ranking that highlights its significance within various scientific communities, NATURAL PRODUCT RESEARCH reflects the complexities and innovations associated with natural compounds and their applications. Researchers, professionals, and students will find valuable insights and breakthroughs that contribute to the understanding of bioactive compounds and their roles in health and environmental sustainability. Access options are available, ensuring that the latest findings are accessible to a global audience. As this journal continues to publish until 2024, it remains an essential resource for those at the forefront of natural product research.

SAR and QSAR in Environmental Research is a leading journal published by Taylor & Francis Ltd, focusing on the integration of Structure-Activity Relationships (SAR) and Quantitative Structure-Activity Relationships (QSAR) within the realm of environmental science. Since its inception in 1993, the journal has been a pivotal platform for disseminating innovative research that bridges the gap between chemistry and environmental sustainability, ranking in the Q3 quartile for Bioengineering, Drug Discovery, and miscellaneous Medicine categories as of 2023. Featuring a compelling collection of peer-reviewed articles, it caters to academic and professional audiences seeking to enhance their understanding of molecular interactions and their implications for environmental health. Although the journal does not currently offer Open Access options, its rigorous editorial standards ensure high-quality, impactful publications that are crucial for advancing methodologies in pharmacology, toxicology, and bioengineering. With an ISSN of 1062-936X and an E-ISSN of 1029-046X, SAR and QSAR in Environmental Research continues to serve as an essential resource for researchers, academics, and practitioners dedicated to innovative approaches in environmental research.

COMPUTATIONAL BIOLOGY AND CHEMISTRY is a distinguished academic journal published by Elsevier Science Ltd, focusing on the dynamic intersection of computational biology, biochemistry, and chemistry. With an ISSN of 1476-9271 and an E-ISSN of 1476-928X, this journal is committed to disseminating high-quality research that employs computational techniques to solve complex biological and chemical problems. As of 2023, the journal holds a substantial impact factor reflecting its significance and rigorous peer-review process, categorized in the Q2 quartile for both Computational Mathematics and Organic Chemistry, alongside Q3 classifications in Biochemistry and Structural Biology. With a continuous publication history spanning from 2003 to 2024, it serves as a critical resource for researchers, professionals, and students alike. The journal offers various open access options, ensuring that vital research findings are accessible to a global audience, further enhancing collaboration across disciplines. Engage with cutting-edge studies and contribute to the evolving landscape of computational methodologies in the life sciences through this esteemed publication.

Advances in Pharmacological and Pharmaceutical Sciences is a premier open-access journal published by Hindawi Ltd. based in the United Kingdom. Established in 2020, the journal swiftly garnered attention for its commitment to disseminating high-quality research in the realms of pharmacology, toxicology, and pharmaceutical sciences. It holds a commendable impact with notable quartile rankings, including Q2 in both Organic Chemistry and Pharmacology, indicating its importance within these disciplines. By embracing an open-access model, the journal ensures that research findings are widely available, promoting increased visibility and collaboration among researchers, professionals, and students globally. With an ongoing convergence of insights projected through 2024, Advances in Pharmacological and Pharmaceutical Sciences aims to address critical issues and advancements in drug development and therapeutic practices, making it an invaluable resource for those at the forefront of scientific inquiry in pharmacology and related fields.

DRUG DEVELOPMENT RESEARCH is a premier interdisciplinary journal published by Wiley, focusing on the latest advancements in drug discovery, pharmacology, and toxicology. With an ISSN of 0272-4391 and an E-ISSN of 1098-2299, this esteemed publication has been a cornerstone in the field since its inception in 1981 and continues to provide cutting-edge research until 2024. Its rigorous peer-review process and strategic placement in Q2 of the Drug Discovery category, as well as ranking #60 out of 157 in Scopus, underscore the journal's relevance and influence, boasting a respectable 62nd percentile ranking. While the journal does not currently offer open access, it remains a vital resource for researchers, professionals, and students seeking to expand their knowledge on the processes of drug development, identifying new therapeutic targets, and assessing the efficacy and safety of novel compounds. Situated in Hoboken, NJ, this journal stands at the forefront of pharmaceutical innovation, making significant contributions to the advancement of medical science.